Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene

NCT02935517 is registered in ClinicalTrials.gov with Beacon Therapeutics as lead sponsor.

NCT NCT02935517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02935517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
Lead sponsor
Beacon Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 3, 2017
Completion date
August 31, 2026
Enrollment
24 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

achromatopsia